Athira Pharma, Inc. — Director's Dealing 2023

Jan 23, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2023-01-19

Reporting Person: CHURCH KEVIN (Executive VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-18	Common Stock	A	657	$2.74	Acquired	62052	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-19	Stock Option (Right to Buy)	$3.37	A	150000	Acquired	2033-01-18	Common Stock (150000)	Direct

Footnotes

F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c).

F2: The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022.

F3: In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022.

F4: One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter.